. Author manuscript; available in PMC: 2012 Feb 1.

Published in final edited form as: Expert Rev Anticancer Ther. 2011 Jul;11(7):1091–1103. doi: 10.1586/era.10.231

Table 4.

Prognostic models: Einhorn score.

Factors	Points
Third-line or subsequent chemotherapy	3
Progression ≤4 weeks after cisplatin	2
IGCCCG high-risk stage	2
Stratification	Points
Low risk	0	DFS differs between three groups per log-rank test (p < 0.05)
Intermediate risk	2–3
High risk	4–7

DFS: Disease-free survival; IGCCCG: International Germ Cell Cancer Collaborative Group.

Data taken from [33].